Expanding demand, new adoption and margin improvement for clinical laboratory reagents
First written in FY2016-Q3. 11 of 36 entries say "Advanced", first in FY2018-Q2. Latest entry: 2026-11-13.
Tohoku Chemical moved to the "Worse" side of this theme in 2023.
The whole theme swung hardest in 2019: 3 of 9 companies on the "Worse" side.
1 other company's latest entry also says "Mitigated".
- FY2025RestatedAnnual report
「Reagents and consumables increased due to new adoptions of reagents, despite a decline in the number of COVID-19 tests and changes in testing methods at each facility.」
Despite continuing declines in infection testing and changes in testing methods, reagents and consumables continue to increase due to new reagent adoptions. Medical sales increased, while segment profit declined by 0.9% year on year. - FY2025-H1MitigatedAnnual report
「Reagents and consumables increased due to new adoptions of reagents, despite a decline in the number of COVID-19 tests and changes in testing methods at each facility.」
Despite continuing declines in infection testing and changes in testing methods, reagents and consumables increased due to new reagent adoptions. Medical sales increased, while segment profit was flat year on year. - FY2024-Q2RestatedAnnual report
「Results were below the previous period at each facility due to a decrease in the number of COVID-19 tests and changes in testing methods. As a result, sales declined by ¥950 million, or 11.8% year on year, to ¥7.104 billion, while segment profit (gross profit) declined by ¥115 million, or 14.5% year on year, to ¥678 million.」
Medical sales and segment profit were below the previous period due to a decline in infection testing and changes in testing methods. The same demand-decline factors and lower sales and profit have continued from the previous quarter. - FY2024-Q1WorsenedAnnual report
「Medical sales declined substantially at each facility due to a decrease in the number of COVID-19 tests and changes in testing methods. As a result, sales declined by ¥615 million, or 14.5% year on year, to ¥3.637 billion, while segment profit (gross profit) declined by ¥110 million, or 27.3% year on year, to ¥293 million.」
Medical sales and segment profit were below the same quarter of the previous year due to a decline in infection testing and changes in testing methods. The shift from previously expanding demand and new adoptions to declining demand has appeared in the actual results. - FY2023WorsenedAnnual report
「Clinical laboratory reagent sales were below the previous consolidated fiscal year due to intensified competition and a decline in COVID-19-related test reagents. Sales of related equipment were also below the previous consolidated fiscal year. As a result, total sales declined by ¥1.432 billion, or 9.2% year on year, to ¥14.205 billion, while segment profit (gross profit) declined by ¥64 million, or 4.1% year on year, to ¥1.512 billion.」
The effects of intensified competition and the decline in infection-related test reagents appeared in the full-year results, while related-equipment sales also fell, resulting in lower sales and profit for the clinical laboratory reagent segment. - FY2023-Q3WorsenedAnnual report
「Clinical laboratory reagent sales were below the same quarter of the previous year due to intensified competition and a decline in COVID-19-related test reagents. Sales of related equipment were also below the same quarter of the previous year. As a result, total sales declined by ¥778 million, or 6.8% year on year, to ¥10.607 billion, while segment profit (gross profit) declined by ¥15 million, or 1.3% year on year, to ¥1.134 billion.」
Clinical laboratory reagent sales declined due to intensified competition and a decrease in infection-related test reagents, while related-equipment sales also fell. The segment as a whole reported lower sales and profit, with profit also turning lower after the previous quarter's decline in sales and slight increase in profit. - FY2023-Q2WorsenedAnnual report
「Clinical laboratory reagent sales were below the same quarter of the previous year due to intensified competition and a decline in COVID-19-related test reagents. Sales of related equipment were also below the same quarter of the previous year. As a result, total sales declined by ¥318 million, or 4.1% year on year, to ¥7.458 billion, while segment profit (gross profit) increased by ¥5 million, or 0.7% year on year, to ¥787 million.」
Clinical laboratory reagent sales fell due to intensified competition and a decline in infection-related test reagents, while related-equipment sales also declined, resulting in lower segment sales. Segment profit, however, increased by 0.7%. - FY2023-Q1RestatedAnnual report
「Clinical laboratory reagent sales exceeded the same quarter of the previous year due to growth in COVID-19-related test reagents, despite the impact of intensified competition. Sales of related equipment were below the same quarter of the previous year. As a result, total sales increased by ¥195 million, or 5.2% year on year, to ¥3.956 billion, while segment profit (gross profit) increased by ¥46 million, or 13.0% year on year, to ¥401 million.」
Despite the impact of intensified competition, clinical laboratory reagent sales increased due to growth in infection-related test reagents. Related-equipment sales were below the same quarter of the previous year, but the segment as a whole continued to report higher sales and profit. - FY2022AdvancedAnnual report
「Clinical laboratory reagent sales exceeded the previous consolidated fiscal year due to growth in COVID-19-related test reagents and the emerging upward trend in specimen testing, despite the impact of intensified competition. Sales of related equipment were below the previous consolidated fiscal year due to the application of the revenue recognition accounting standards and other factors. As a result, total sales increased by ¥967 million, or 6.6% year on year, to ¥15.637 billion, while segment profit (gross profit) increased by ¥143 million, or 10.0% year on year, to ¥1.577 billion.」
Despite the impact of intensified competition, the clinical laboratory reagent segment reported higher sales and profit for the full year due to growth in infection-related test reagents and the upward trend in specimen testing. - FY2022-Q3AdvancedAnnual report
「Clinical laboratory reagent sales exceeded the same quarter of the previous year due to growth in COVID-19-related test reagents, despite the impact of intensified competition. Sales of related equipment were below the same quarter of the previous year due to the application of the revenue recognition accounting standards and other factors. As a result, total sales increased by ¥479 million, or 4.4% year on year, to ¥11.386 billion, while segment profit (gross profit) increased by ¥121 million, or 11.8% year on year, to ¥1.150 billion.」
Despite the impact of intensified competition, clinical laboratory reagent sales exceeded the same quarter of the previous year due to growth in infection-related test reagents, resulting in higher sales and profit for the segment as a whole. Related-equipment sales were below the same quarter of the previous year due to the application of the revenue recognition accounting standards and other factors. - FY2022-Q2AdvancedAnnual report
「Clinical laboratory reagent sales exceeded the same quarter of the previous year due to growth in COVID-19-related test reagents, despite the impact of intensified competition. Sales of related equipment were below the same quarter of the previous year due to the application of the revenue recognition accounting standards and other factors. As a result, total sales increased by ¥454 million, or 6.2% year on year, to ¥7.776 billion, while segment profit (gross profit) increased by ¥78 million, or 11.2% year on year, to ¥781 million.」
Despite the impact of intensified competition, the clinical laboratory reagent segment reported higher sales and profit due to growth in infection-related test reagents. Related-equipment sales were below the same quarter of the previous year due to the application of the revenue recognition accounting standards and other factors. - FY2022-Q1AdvancedAnnual report
「Clinical laboratory reagent sales exceeded the same quarter of the previous year due to growth in COVID-19-related test reagents, despite the impact of intensified competition. Sales of related equipment also exceeded the same quarter of the previous year as orders for analytical equipment and other items increased. As a result, total sales increased by ¥265 million, or 7.6% year on year, to ¥3.761 billion, while segment profit (gross profit) increased by ¥39 million, or 12.5% year on year, to ¥355 million.」
Despite the impact of intensified competition, the clinical laboratory reagent segment reported higher sales and profit due to growth in infection-related test reagents and orders for analytical equipment and other items. - FY2021AdvancedAnnual report
「Clinical laboratory reagent sales significantly exceeded the previous consolidated fiscal year due to growth in COVID-19-related test reagents and the emerging upward trend in specimen testing, despite the impact of intensified competition. Sales of related equipment also significantly exceeded the previous consolidated fiscal year as COVID-19-related consumables and equipment increased substantially.」
The clinical laboratory reagent segment reported substantial increases in sales and profit for the full year due to growth in infection-related test reagents, consumables and equipment, together with the upward trend in specimen testing. - FY2021-Q3AdvancedAnnual report
「Clinical laboratory reagent sales significantly exceeded the same quarter of the previous year due to growth in COVID-19-related test reagents and the emerging upward trend in specimen testing, despite the impact of intensified competition. Sales of related equipment also significantly exceeded the same quarter of the previous year as COVID-19-related consumables and equipment increased substantially. As a result, total sales increased substantially by ¥2.319 billion, or 27.0%, to ¥10.907 billion, while segment profit (gross profit) increased substantially by ¥193 million, or 23.1%, to ¥1.028 billion.」
Despite the impact of intensified competition, the clinical laboratory reagent segment reported substantial increases in sales and profit due to growth in infection-related test reagents, consumables and equipment, together with the upward trend in specimen testing. - FY2021-Q2AdvancedAnnual report
「Clinical laboratory reagent sales significantly exceeded the same quarter of the previous year due to growth in COVID-19-related test reagents and the emerging upward trend in specimen testing, despite the impact of intensified competition. Sales of related equipment also significantly exceeded the same quarter of the previous year as COVID-19-related consumables and equipment increased substantially. As a result, total sales increased substantially by ¥1.502 billion, or 25.8%, to ¥7.322 billion, while segment profit (gross profit) increased by ¥140 million, or 25.0%, to ¥702 million.」
The clinical laboratory reagent segment reported substantial increases in sales and profit due to growth in infection-related test reagents, consumables and equipment, together with the upward trend in specimen testing. - FY2021-Q1AdvancedAnnual report
「Clinical laboratory reagent sales significantly exceeded the same quarter of the previous year due to growth in COVID-19-related test reagents and other factors, despite the impact of intensified competition. Sales of related equipment also exceeded the same quarter of the previous year as COVID-19-related consumables and equipment increased. As a result, total sales increased by ¥598 million, or 20.7%, to ¥3.495 billion, while segment profit (gross profit) increased by ¥54 million, or 20.9%, to ¥315 million.」
Despite the impact of intensified competition, the clinical laboratory reagent segment reported substantial increases in sales and profit due to growth in COVID-19-related test reagents, consumables and equipment. - FY2020AdvancedAnnual report
「Clinical laboratory reagent sales exceeded the same period of the previous year due to new adoptions and growth in test reagents for COVID-19, despite a decline in the number of specimen tests caused by the COVID-19 pandemic.」
Despite a decline in the number of specimen tests, clinical laboratory reagent sales exceeded the previous year for the full year due to new adoptions and growth in test reagents for COVID-19. - FY2020-Q3RestatedAnnual report
「Clinical laboratory reagent sales exceeded the same quarter of the previous year due to new projects and other factors, despite the impact of intensified competition and a decline in the number of specimens. Sales of related equipment were below the same quarter of the previous year because orders for equipment and other items were delayed. As a result, total sales increased by ¥24 million, or 0.3%, to ¥8.587 billion, while segment profit (gross profit) increased by ¥20 million, or 2.6%, to ¥835 million.」
While intensified competition, a decline in the number of specimens and delays in orders for related equipment continued, clinical laboratory reagent sales exceeded the same quarter of the previous year due to new projects and other factors, and the segment as a whole continued to report higher sales and profit. - FY2020-Q2AdvancedAnnual report
「Clinical laboratory reagent sales exceeded the same quarter of the previous year due to new projects and other factors, despite the impact of intensified competition and a decline in the number of specimens. Sales of related equipment were below the same quarter of the previous year because orders for equipment and other items were delayed. As a result, total sales increased by ¥39 million, or 0.7%, to ¥5.820 billion, while segment profit (gross profit) increased by ¥7 million, or 1.3%, to ¥562 million.」
Despite the impact of intensified competition and a decline in the number of specimens, clinical laboratory reagent sales exceeded the same quarter of the previous year due to new projects and other factors. Related-equipment sales fell because orders were delayed, but the segment as a whole returned to higher sales and profit. - FY2020-Q1ReframedAnnual report
「Clinical laboratory reagent sales exceeded the same quarter of the previous year due to orders for new projects and other factors, despite the impact of intensified competition. Sales of related equipment were below the same quarter of the previous year, partly because orders for equipment and other items were delayed. As a result, total sales declined by ¥84 million, or 2.8%, to ¥2.896 billion, while segment profit (gross profit) declined by ¥17 million, or 6.1%, to ¥261 million.」
Amid continuing intensified competition, clinical laboratory reagent sales exceeded the same quarter of the previous year due to orders for new projects and other factors. Related-equipment sales fell because orders were delayed, and the segment as a whole reported lower sales and profit. - FY2019WorsenedAnnual report
「Clinical laboratory reagent sales were below the same period of the previous year despite new adoptions of test reagents, due to intensified competition and a decline in the number of specimen tests. Sales of related equipment exceeded the same period of the previous year due to new equipment adoptions and other factors. As a result, total sales declined by ¥150 million, or 1.2%, to ¥12.270 billion, while segment profit (gross profit) declined by ¥47 million, or 4.0%, to ¥1.149 billion.」
Despite new adoptions and growth in related equipment, the clinical laboratory reagent segment reported lower sales and profit due to intensified competition and a decline in the number of specimen tests. - FY2019-Q3WorsenedAnnual report
「Clinical laboratory reagent sales were below the same quarter of the previous year, partly due to the impact of intensified competition. Sales of related equipment were also below the same quarter of the previous year because there had been a large project in the previous quarter. As a result, total sales declined by ¥905 million, or 9.6%, to ¥8.563 billion, while segment profit (gross profit) declined by ¥73 million, or 8.3%, to ¥814 million.」
Clinical laboratory reagent sales fell due to intensified competition, while related-equipment sales also fell because of the reaction to a large project in the previous quarter, resulting in lower sales and profit for the segment as a whole. - FY2019-Q2WorsenedAnnual report
「Clinical laboratory reagent sales were below the same quarter of the previous year, partly due to the impact of intensified competition. Sales of related equipment were also below the same quarter of the previous year because there had been a large project in the previous quarter. As a result, total sales declined by ¥955 million, or 14.2%, to ¥5.780 billion, while segment profit (gross profit) declined by ¥73 million, or 11.6%, to ¥555 million.」
Clinical laboratory reagent sales fell due to intensified competition, while related-equipment sales also fell because of the reaction to a large project in the previous quarter, resulting in lower sales and profit for the segment as a whole. - FY2019-Q1WorsenedAnnual report
「Clinical laboratory reagent sales were below the same quarter of the previous year, partly due to intensified competition. Consumables and equipment for related equipment were also below the same quarter of the previous year. As a result, total sales declined by ¥214 million, or 6.7%, to ¥2.981 billion, while segment profit (gross profit) declined by ¥3 million, or 1.1%, to ¥278 million.」
Clinical laboratory reagent sales fell below the same quarter of the previous year due to intensified competition, and consumables and equipment for related equipment were also below the previous year, resulting in lower sales and profit for the segment as a whole. - FY2018ReframedAnnual report
「Clinical laboratory reagent sales were below the same period of the previous year because test items were adopted on a one-off basis in that period. Sales of related equipment exceeded the same period of the previous year because there was a large project. As a result, total sales increased by ¥161 million, or 1.3%, to ¥12.421 billion, while segment profit (gross profit) increased by ¥32 million, or 2.8%, to ¥1.197 billion.」
Rather than the intensified competition cited through the third quarter, the company attributed the results to the reaction to one-off adoption in the previous period and a large project for related equipment. The segment as a whole reported higher sales and profit. - FY2018-Q3ReframedAnnual report
「Clinical laboratory reagent sales were below the same quarter of the previous year, partly due to the impact of intensified competition. Sales of related equipment exceeded the same quarter of the previous year because there was a large project. As a result, total sales increased by ¥242 million, or 2.6%, to ¥9.469 billion, while segment profit (gross profit) increased by ¥33 million, or 3.9%, to ¥888 million.」
Clinical laboratory reagent sales had exceeded the same quarter of the previous year through the previous quarter, but fell below it this time because of intensified competition. Meanwhile, the large project for related equipment resulted in higher sales and profit for the segment as a whole. - FY2018-Q2AdvancedAnnual report
「Clinical laboratory reagent sales exceeded the same quarter of the previous year despite the impact of intensified competition. Sales of related equipment also exceeded the same quarter of the previous year because there was a large project. As a result, total sales increased by ¥477 million, or 7.6%, to ¥6.736 billion, while segment profit (gross profit) increased by ¥50 million, or 8.8%, to ¥628 million.」
Despite the impact of intensified competition, clinical laboratory reagent sales exceeded the same quarter of the previous year, while related-equipment sales increased due to a large project. The segment as a whole reported higher sales and profit. - FY2018-Q1ReframedAnnual report
「Clinical laboratory reagent sales were slightly below the same quarter of the previous year, partly due to intensified competition. Sales of related equipment exceeded the same quarter of the previous year as consumables and equipment grew steadily. As a result, total sales increased by ¥150 million, or 4.9%, to ¥3.196 billion, while segment profit (gross profit) increased by ¥15 million, or 6.0%, to ¥281 million.」
The factors cited changed from the reaction to one-off adoption and a large project in the previous period to intensified competition for clinical laboratory reagents and growth in consumables and equipment for related equipment. The segment as a whole reported higher sales and profit. - FY2017RestatedAnnual report
「Clinical laboratory reagent sales were below the same period of the previous year because test items were adopted on a one-off basis in that period. Sales of related equipment were also below the same period of the previous year because there was a large project in the previous period. As a result, total sales declined by ¥754 million, or 5.8%, to ¥12.259 billion, while segment profit (gross profit) declined by ¥41 million, or 3.5%, to ¥1.164 billion.」
The decline in sales and profit caused by the reaction to one-off adoption and a large project in the previous period was also cited as a factor for the full year. - FY2017-Q3RestatedAnnual report
「Clinical laboratory reagent sales were below the same quarter of the previous year because test items were adopted on a one-off basis in that quarter. Sales of related equipment were also below the same quarter of the previous year because there was a large project in the previous quarter. As a result, total sales declined by ¥550 million, or 5.6%, to ¥9.226 billion, while segment profit (gross profit) declined by ¥22 million, or 2.6%, to ¥854 million.」
Sales and profit for both clinical laboratory reagents and related equipment continue to decline, reflecting the reaction to one-off adoption and a large project in the same quarter of the previous year. - FY2017-Q2RestatedAnnual report
「Clinical laboratory reagent sales were below the same quarter of the previous year because test items were adopted on a one-off basis in that quarter. Sales of related equipment were also below the same quarter of the previous year because there was a large project in the previous quarter. As a result, total sales declined by ¥465 million, or 6.9%, to ¥6.258 billion, while segment profit (gross profit) declined by ¥16 million, or 2.8%, to ¥577 million.」
As in the previous quarter, sales and profit declined for both clinical laboratory reagents and related equipment, reflecting the reaction to one-off adoption and a large project in the same quarter of the previous year. - FY2017-Q1WorsenedAnnual report
「Clinical laboratory reagents were below the same quarter of the previous year because there had been spot adoption of specimen-testing items in the same quarter of the previous year. Related equipment was also below the same quarter of the previous year because there had been a large project in that quarter. As a result, total sales decreased by ¥279 million, or 8.4%, to ¥3,045 million, while segment profit (gross profit) decreased by ¥24 million, or 8.6%, to ¥265 million.」
Sales and segment profit for clinical laboratory reagents both declined, reflecting the reaction to one-off adoption of test items and a large related-equipment project in the same quarter of the previous year. - FY2016RestatedAnnual report
「Clinical laboratory reagents exceeded the previous consolidated fiscal year due to increased demand and the new adoption of specimen-testing items, among other factors. Related equipment was slightly below the previous consolidated fiscal year, as consumables remained sluggish despite new deliveries progressing as planned. As a result, total sales increased by ¥117 million, or 0.9%, to ¥13,014 million, while segment profit (gross profit) increased by ¥42 million, or 3.7%, to ¥1,206 million due to improved margins.」
Clinical laboratory reagents posted higher sales and profit due to increased demand, new adoption and improved margins, while the disclosure notes sluggish growth in consumables for related equipment. - FY2016-Q3First statedAnnual report
「Clinical laboratory reagents exceeded the same quarter of the previous year due to increased demand and the new adoption of specimen-testing items, among other factors. Related equipment also exceeded the same quarter of the previous year because new deliveries progressed as planned. As a result, total sales increased by ¥432 million, or 4.6%, to ¥9,776 million, while segment profit (gross profit) increased by ¥50 million, or 6.1%, to ¥877 million due to improved margins.」
The disclosure states that sales and profit from clinical laboratory reagents exceeded the same quarter of the previous year against a backdrop of increased demand, the adoption of new testing items, progress with planned new deliveries, and improved margins.